Quantum BioPharma (QNTM) hires Stocks.news in US$250K investor relations push
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Quantum BioPharma Ltd. has engaged IR Agency LLC, operating as Stocks.news, to provide investor relations, marketing, digital community building, news distribution and lead-generation services. The agreement begins on June 8, 2026, runs for six months and carries a fee of US$250,000.
The Agency is arm’s length to Quantum and neither it nor its principals hold, or have rights to acquire, any Quantum securities. The filing also reiterates Quantum’s business focus on therapies for neurodegenerative and metabolic disorders and alcohol misuse, and highlights its economic interest in Unbuzzd through both an equity stake and royalties.
Positive
- None.
Negative
- None.
Key Figures
IR services fee: US$250,000
IR agreement term: 6 months
Unbuzzd ownership stake: 19.84%
+4 more
7 metrics
IR services fee
US$250,000
Six-month investor relations and marketing agreement with IR Agency LLC
IR agreement term
6 months
Duration of investor relations and consulting services starting June 8, 2026
Unbuzzd ownership stake
19.84%
Quantum’s equity interest in Unbuzzd as of March 31, 2026
Initial Unbuzzd royalty rate
7% of sales
Applies until Quantum has received $250 million in royalty payments
Royalty threshold
$250 million
Cumulative royalty level at which rate drops from 7% to 3%
Ongoing Unbuzzd royalty rate
3% of sales
Royalty rate in perpetuity after $250 million in cumulative payments
Form type
Form 6-K
Report of foreign private issuer under Exchange Act
Key Terms
arm’s-length, royalty payments, forward-looking statements, foreign private issuer, +1 more
5 terms
arm’s-length financial
"The Agency is arm’s-length to the Company and neither the Agency nor its principals hold an equity interest"
A transaction or relationship carried out on normal market terms between independent parties who have no special ties or influence over one another. For investors, arm’s-length dealings matter because they reduce the risk of hidden favoritism or distorted prices—think of buying a used car from a stranger at the going rate rather than getting a sweetheart deal from a family member—so financial statements and valuations better reflect true market value.
royalty payments financial
"The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™"
Payments made to the owner of an asset, patent, trademark, mineral right, or creative work in exchange for permission to use it; they are typically a percentage of sales or a fixed fee per unit sold. For investors, royalty payments represent a steady income stream tied to the underlying product’s sales performance, similar to collecting rent from tenants — predictable cash flow that can reduce risk or add value when evaluating a company’s revenue sources.
forward-looking statements regulatory
"This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
foreign private issuer regulatory
"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
multiple sclerosis medical
"Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis"
A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.
FAQ
What investor relations agreement did Quantum BioPharma (QNTM) announce in this 6-K?
Quantum BioPharma entered a six-month investor relations and consulting agreement with IR Agency LLC (Stocks.news). The Agency will provide marketing, digital community building, news distribution and lead-generation services to help communicate information about the company to the financial community.
How much will Quantum BioPharma (QNTM) pay IR Agency LLC under the new agreement?
Quantum will pay IR Agency LLC a fee of US$250,000 for six months of investor relations, marketing and lead-generation services. The agreement covers company profiles, media distribution and building a digital community focused on the company’s story and news flow.
When does Quantum BioPharma’s (QNTM) investor relations agreement with Stocks.news start and how long does it last?
The investor relations agreement with Stocks.news, through IR Agency LLC, starts on June 8, 2026 and runs for six months. During this period, the Agency will focus on outreach to investors, media distribution and related marketing activities for Quantum BioPharma.
What is Quantum BioPharma’s ownership and royalty arrangement with Unbuzzd?
Quantum holds a 19.84% ownership interest in Unbuzzd as of March 31, 2026. It is also entitled to a 7% royalty on unbuzzd™ sales until cumulative payments reach $250 million, after which the royalty rate decreases to 3% in perpetuity under their agreement.
What therapeutic areas does Quantum BioPharma (QNTM) focus on?
Quantum BioPharma is a biopharmaceutical company focused on innovative therapies and technologies for neurodegenerative and metabolic disorders, and alcohol misuse disorders. Its lead compound, Lucid-MS, targets myelin degradation in multiple sclerosis, while it also retains rights to develop pharmaceutical formulations related to its UNBUZZD™ technology.